Get the Stockscreener App
1.21
6.20%
-0.08
After Hours:
1.23
0.02
+1.65%
Pmv Pharmaceuticals Inc stock is traded at $1.21, with a volume of 357.04K.
It is down -6.20% in the last 24 hours and down -15.38% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
See More
Previous Close:
$1.29
Open:
$1.28
24h Volume:
357.04K
Relative Volume:
0.60
Market Cap:
$64.68M
Revenue:
Net Income/Loss:
$-78.34M
P/E Ratio:
-0.8165
EPS:
-1.4819
Net Cash Flow:
$-75.02M
1W Performance:
-20.39%
1M Performance:
-15.38%
6M Performance:
-11.68%
1Y Performance:
-15.97%
1-Day Range:
$1.20
$1.30
1-Week Range:
$1.20
$1.55
52-Week Range:
$1.02
$1.91
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.21 | 64.68M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-26 | Initiated | Ladenburg Thalmann | Buy |
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
PMV appoints Matt Eckler: what the 2027 filing means for PMV Pharmaceuticals stock - ad-hoc-news.de
PMV Pharmaceuticals adds Matt Eckler and PMV Pharmaceuticals stock posts 21.60 percent YTD - ad-hoc-news.de
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Yahoo Finance
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity - Seeking Alpha
PMV Pharmaceuticals stock adds Matt Eckler to its board opening the next clinical chapter - AD HOC NEWS
PMV Pharmaceuticals stock adds Matt Eckler to its board opening the next clinical chapter - AD HOC NEWS
PMV PHARMACEUTICALS APPOINTS MATT ECKLER, PH.D., TO BOARD OF DIRECTORS - Moomoo
PMV Pharmaceuticals Appoints Matt Eckler to Board Ahead of 2027 NDA Filing - citybiz
PMV Pharmaceuticals Director Matthew Joseph Eckler Granted 84,000 Stock Options - Kalkine Media
PMV Pharmaceuticals Appoints Matthew Joseph Eckler as Director; Files Initial Ownership Statement with SEC - Kalkine Media
Phase 2 single-drug enrollment is complete. PMV Pharma (PMVP) plans an ovarian cancer drug application. - Stock Titan
PMV Pharmaceuticals adds biotech investor to its board - StreetInsider
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors - Yahoo Finance
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors - GlobeNewswire
A Q1 2027 application for accelerated approval is planned for PMV’s ovarian cancer drug. - Stock Titan
Biotech Stocks At 52-Week HighsKOD, MASS, OBIO, CDNA, PMVP - RTTNews
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Zacks Investment Research
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Yahoo Finance
An investor group in PMV Pharmaceuticals (NASDAQ: PMVP) is held just under a 10% stake by its warrant terms. - Stock Titan
PMV Pharma appoints Philip Herman as CCO - thepharmaletter.com
symbol__ Stock Quote Price and Forecast - cnn.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - Yahoo Finance
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Australia
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - GlobeNewswire
PMVP SEC Filings, Jul-Aug 2025PMV Pharmaceuticals, Inc. Filing Archive - Stock Titan
PMV Pharmaceuticals stock gains as biotech peers advance - ad-hoc-news.de
PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target - ad-hoc-news.de
PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering - TipRanks
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance
PMV Pharmaceuticals (PMVP) Announces $50.8M Oversubscribed Offering Amid Mixed Market Signals - GuruFocus
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals (PMVP) Updates Interim Ovarian Cancer Trial Results Amid Valuation Challenges - GuruFocus
PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data - TipRanks
PMV Pharmaceuticals reports 46% ORR in ovarian cohort, plans NDA filing in Q1 2027 - TradingView
PMV Pharma Announces Proposed Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals, Inc. Announces Updated Interim Ovarian Cancer Data for Rezatapopt Monotherapy From PYNNACLE Phase 2 Pivotal Trial - marketscreener.com
PMV Pharmaceuticals Announces Updated Promising Rezatapopt - GlobeNewswire
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering - Yahoo Finance
Ovarian cancer trial reports a 46% response rate; FDA filing planned - Stock Titan
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial - Yahoo Finance
ETFs Investing in PMV Pharmaceuticals, Inc. Stocks - TradingView
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
| OrbiMed Private Investments V, | Shareholder |
Oct 23 '25 |
Proposed Sale |
1.52 |
1,000,000 |
1,520,000 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):